Like most compounded GLP-1 telehealth providers, Henry Meds's program has shifted since the FDA's 2024-2025 shortage resolutions — expect more variability in medication format, dosing structure, and pricing than in years past.
If predictable, flat pricing matters to you regardless of how the compounded landscape shifts, Luma Health's semaglutide ($197/month) and tirzepatide ($297/month) are priced the same regardless of dose.
The compounded GLP-1 telehealth market looks different in 2026 than it did even a year or two ago, and Henry Meds — like most providers in this space — has adjusted its program accordingly. Here's what's changed at a category level, and what to watch for regardless of which specific provider you're considering.
The Industry-Wide Context
The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That shift narrowed the legal basis for routine, cost-driven "essentially a copy" compounding across the entire industry — not specific to any one company. In response, providers across the market have adjusted their offerings: some discontinued certain compounded products entirely, others shifted toward alternative formats (like oral tablets or sublingual drops) or longer program commitments, and pricing structures have generally become more variable and dose-dependent than the simple flat rates common a couple of years ago.
What to Verify With Any Provider Right Now
Given how much has shifted, it's worth directly confirming several things before enrolling or renewing with any compounded GLP-1 provider in 2026: which specific medication format is currently offered (injectable, oral tablet, sublingual), what the current program length and delivery schedule looks like (some programs now bundle multiple months of medication into a single upfront commitment), what the actual all-in monthly cost is at your expected dose, and which licensed pharmacy is preparing your medication.
Where a flat monthly subscription was once standard, many compounded GLP-1 programs now bundle several months of medication into upfront commitments (for example, medication delivered every 60-90 days as part of a 6- or 12-month program). This isn't inherently a problem, but it does mean comparing "monthly price" across providers requires understanding the underlying commitment structure, not just the headline number.
Why Pricing Has Gotten Harder to Compare
Compounded GLP-1 pricing across the market as a whole has become considerably more variable than it was during the shortage era, when flat, dose-independent pricing was common. Total monthly costs across providers can now range broadly depending on dose, program length, and whether pricing is flat or tiered. When comparing options, it's worth calculating your actual expected cost at your target maintenance dose over a realistic treatment timeline, rather than comparing advertised starting prices.
What Hasn't Changed
The clinical fundamentals remain the same regardless of which provider or program structure you choose: eligibility criteria (generally BMI ≥30, or ≥27 with a weight-related condition), the importance of gradual dose titration to manage side effects, and the value of a real medical evaluation before starting treatment. Those fundamentals should be non-negotiable with any provider, whatever else has changed around them.
What to Prioritize When Comparing Providers
- The exact medication format and current availability
- Your all-in monthly cost at your expected maintenance dose
- The program commitment length and cancellation terms
- Flat pricing that doesn't increase as your dose does
- Transparency about which licensed pharmacy prepares your medication
- A real medical evaluation, not a rubber-stamp approval
Flat pricing that
doesn't shift on you
Compounded semaglutide at $197/month or tirzepatide at $297/month — the same price at every dose, with a real medical evaluation included.
Get Started → Or start your free health assessmentFrequently Asked Questions
The FDA's 2024-2025 determinations that the tirzepatide and semaglutide shortages were resolved narrowed the legal basis for routine compounding industry-wide, prompting providers broadly to adjust their offerings, formats, and pricing structures.
The current medication format and availability, your all-in monthly cost at your target dose, the program length and commitment terms, and which licensed pharmacy prepares the medication.
Yes, many providers have shifted toward bundling multiple months of medication into a single upfront commitment (for example, 6 or 12 months), rather than simple month-to-month billing.
Yes, when sourced from a provider that's transparent about the medication format, pricing, program terms, and licensed pharmacy preparing it. The regulatory landscape has narrowed who can legally offer it, not eliminated it entirely.
Eligibility criteria (BMI thresholds), gradual dose titration, and a real medical evaluation before starting. These should be non-negotiable with any provider, regardless of pricing or format changes.
Luma Health's flat pricing ($197/month semaglutide, $297/month tirzepatide, regardless of dose) is designed to stay predictable for patients, though we'd encourage confirming current terms directly at signup, as with any provider.
References
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.gov. 2025. FDA.gov
- U.S. Food and Drug Administration. Human Drug Compounding and the FD&C Act. FDA.gov. FDA.gov
- GoodRx. The Tirzepatide Shortage Is Over: Here's What You Need to Know. GoodRx.com. 2026. GoodRx.com
- U.S. Food and Drug Administration. Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide). FDA.gov. 2025. FDA Drug Approvals Database